Dr. Christopher J. Forlenza
Claim this profileMemorial Sloan Kettering Cancer Center
Expert in Lymphoma
Expert in Langerhans Cell Histiocytosis
18 reported clinical trials
38 drugs studied
About Christopher J. Forlenza
Education:
- Earned an MD (Doctor of Medicine) from an unspecified medical school.
Experience:
- Serves as a Pediatric Hematologist-Oncologist at Memorial Sloan Kettering Cancer Center, with a specialization in pediatric lymphomas.
- An integral part of the Pediatric Lymphoma Service team, focusing on comprehensive care for children, adolescents, and young adults.
- Works closely with a multidisciplinary team to ensure holistic care and support for patients and their families.
Area of expertise
1Lymphoma
Global LeaderStage IV
Stage I
Stage II
2Langerhans Cell Histiocytosis
Global LeaderStage I
Stage II
MTOR positive
Affiliated Hospitals
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Nassau
Clinical Trials Christopher J. Forlenza is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
DAY101
for Langerhans Cell Histiocytosis
This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting1 award Phase 228 criteria
More about Christopher J. Forlenza
Clinical Trial Related7 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Christopher J. Forlenza has experience with
- Nivolumab
- Brentuximab Vedotin
- Erdafitinib
- Olaparib
- Palbociclib
- Selpercatinib
Breakdown of trials Christopher J. Forlenza has run
Lymphoma
Langerhans Cell Histiocytosis
Histiocytosis
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher J. Forlenza specialize in?
Christopher J. Forlenza focuses on Lymphoma and Langerhans Cell Histiocytosis. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage I.
Is Christopher J. Forlenza currently recruiting for clinical trials?
Yes, Christopher J. Forlenza is currently recruiting for 6 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Christopher J. Forlenza has studied deeply?
Yes, Christopher J. Forlenza has studied treatments such as Nivolumab, Brentuximab Vedotin, Erdafitinib.
What is the best way to schedule an appointment with Christopher J. Forlenza?
Apply for one of the trials that Christopher J. Forlenza is conducting.
What is the office address of Christopher J. Forlenza?
The office of Christopher J. Forlenza is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.